Location: The Bronx NY, New York NY, Hackensack NJ,
Sponsor: Xencor, Inc.
Sex: All
Age: 15+
Code: NCT06276491
Phase1, Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
for
Biliary Tract Cancer, Breast Cancer, Cervical Cancer,
Location: Boston MA, Miami FL, Denver CO, Nashville TN,
Sponsor: ModeX Therapeutics, An OPKO Health Company
Sex: All
Age: 18+
Code: NCT06239194
Phase1, Phase2, Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
for
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma,
Location: Boston MA, Philadelphia PA, Charlottesville VA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18+
Code: NCT04104776
Phase1, Phase2, Recruiting
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
for
Ovarian Cancer, Endometrial Cancer,
Location: Boston MA, Fairfax VA, Orlando FL, Nashville TN,
Sponsor: ArriVent BioPharma, Inc.
Sex: Female
Age: 18+
Code: NCT07755436
Phase1, Recruiting
Multimedia Aid for Genetic Testing in Gynecologic Oncology
for
Ovary Cancer, Endometrial Cancer
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center
Sex: Female
Age: 18+
Code: NCT07084168
Recruiting
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
for
Platinum-resistant Ovarian Cancer,
Location: Montreal, Toronto, Pittsburgh PA, Grand Rapids MI,
Sponsor: MacroGenics
Sex: Female
Age: 18+
Code: NCT06730347
Phase2, Recruiting
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Location: Lake Success NY, Grand Rapids MI, Houston TX,
Sponsor: MacroGenics
Sex: All
Age: 18+
Code: NCT06242470
Phase1, Recruiting
New
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy